Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +17.86% | +17.86% | +9.27% |
May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.27% | 60.66M | - | ||
+7.04% | 72.03B | A | ||
-10.86% | 5.14B | A- | ||
+46.43% | 4.6B | - | ||
+5.38% | 3.96B | B- | ||
-16.20% | 2.5B | C- | ||
+20.84% | 2.43B | B | ||
-26.20% | 2.32B | - | ||
+19.92% | 2.18B | - | - | |
+8.15% | 1.72B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ORX Stock
- ORXOY Stock
- Ratings Orexo AB